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SUMMARY 
 
Title: 
Damage to Oligodendrocytes and Axons Following Endothelin 1-induced Focal 
Cerebral Ischemia  
Aims: 
The purpose of this study was to characterize the regional patterns of neuronal and 
axonal injury in immature rats following FCI. 
Methods: 
Experiments were performed in Wistar rats on postnatal day 12 and 25. FCI was 
induced by the intracerebral injection of Endothelin 1 (ET-1). Neuronal and axonal 
injury was assessed by the means of qualitative morphologic methods.  
Results: 
Our findings demonstrate that ET-1 induced FCI in the developing rat brain generates 
neuronal injury in the ipsilateral cortex and a distinct pattern of subcortical neuronal 
injury. The spatial spread of the damage to myelinated fibers seemed to be bigger than 
the extent of the area, where degenerating neurons were observed. 
Keywords:  
Oligodendrocyte, Focal cerebral ischemia, Endothelin-1, Myelin  
SOUHRN 
 
Název: 
Poškození axonů a oligodendrocytů u fokální mozkové ischémie vyvolané aplikací 
Endothelinu-1.  
Cíle práce: 
Charakterizovat poškození nervových buněk a axonů na modelu fokální mozkové 
ischémie v nezralé mozkové tkáni.  
Metody:  
Experimentální studie proběhla na  jedincích laboratorního  potkana ve věku 12ti a 
25ti  dní. Fokální mozková ischémie byla vyvolána aplikací ET-1. Hodnocení 
poškození nervových buněk a axonů se provádělo kvalitativně popisně. Využity 
k tomu účelu byly morfologické metody. 
Výsledky: 
Demonstrují, že aplikace ET-1 do nezralé mozkové tkáně potkanů, způsobuje lézi 
v ipsilaterálních kortikálních, ale i subkortikálních strukturách. Oblast, kde bylo 
nalezeno poškození myelinizovaných vláken byla většího rozsahu než oblast, kde byly 
lokalizovány degenerující neurony. 
Klíčová slova:  
Oligodendrocyt, Axon, Fokální mozková ischémie, Endothelin-1, Myelin  
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1. INTRODUCTION 
 
There has been growing awareness among neurobiologists in recent years regarding the 
importance of understanding the molecular interactions that occur between neurons and 
glia in the CNS, particularly as it pertains to CNS pathological states with major 
impacts on society, such as trauma, stroke, and neurodegenerative diseases. It is now 
recognized that neurons are highly dependent on glial cells for providing structural and 
metabolic support constitutively, and that the extent of neurodegeneration and the 
degree to which neurons are protected from neurodegeneration during CNS injury and 
disease are influenced greatly by the activity of non-neuronal glial cells. (52) 
White matter and gray matter are vulnerable to ischemic damage on human stroke, and 
functional deficits are generally a reflection of damage to both neuronal perikarya and 
their myelinated axons. (93) Oligodendrocytes, a major cellular component of white 
matter, are the only CNS myelin-forming cells and thus play a pivotal role in the proper 
execution of neural functions. (83) The myelin sheath is a multilamellar membrane 
structure wrapped around the axon, enabling the saltatory conduction of nerve impulses 
in vertebrates. (51)  
Very little is known about the role of oligodendrocytes in early stage of cerebral 
ischemia. Interestingly, and in contrast to previous concepts (50), oligodendrocytes 
appear to be highly vulnerable to cerebral ischemia. (49, 88) 
Axons are essential for the functioning of the nervous system, which in humans, is 
composed of nearly 45% white matter. (24) Axonal damage is a consequence of 
ischemic stroke and head injury (66,100) as well as a number of chronic neurological 
conditions. The mechanisms of axonal pathology are poorly understood when compared 
with the detailed characterization of the mechanisms that lead to neuronal perikaryal 
damage. (24) 
In contrast to the situation in the PNS, where injured axons often regenerate 
successfully over long distances, axonal regeneration is minimal or absent in the adult 
mammalian CNS. Therefore, CNS trauma often results in severe and permanent 
deficits. It is now well accepted that the inability of CNS axons to regenerate is 
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crucially influenced by the presence of non-neuronal inhibitory factors in the axonal 
environment. (41) 
There are several known myelin-derived proteins, which show axon growth-inhibitory 
properties limiting anatomical and functional recovery. Such molecules are myelin-
associated glycoprotein (60, 84), oligodendrocyte-myelin glycoprotein (94), chondroitin 
sulfate proteoglycans (61), and the newly identified Nogo family. (60, 11, 63) 
Combinations of treatments may be required to deal with the full complexity of CNS 
injury. Understanding the mechanisms of cell death of oligodendrocytes, and their 
interactions with axons, may help prevent myelin loss, and preserve neurological 
function. (58) In the development of neuroprotective drugs for clinical use in stroke, the 
efficacy of a drug, particularly with regard to functional recovery, is ultimately 
dependent on its ability to protect against both grey and white matter damage. (36) 
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2. THEORETICAL BACKGROUND 
 
2.1. CELLS OF THE BRAIN 
The brain, like all other organs, is made up of vast numbers of cells. Unlike some 
organs, however, the brain contains a wide variety of cell types. In the middle of the 
nineteenth century the German anatomist Rudolf Virchow recognized that cells in the 
brain could be divided into two distinct groups: neurons, and far more numerous group 
of cells that appear to surround the neurons and fill the space between them. Virchow 
called this second category of cell the neuralgia. (45) 
Historically, gill cells were viewed as a type of central nervous system connective tissue 
whose main function was to provide support to the true functional cells of the brain, the 
neurons. This firmly entrenched concept remains virtually unquestioned for the better 
part of a century. But gill cells are neither connective tissue nor mere supportive cells. 
In contrast to early beliefs, glial cells are now recognized as intimate partners with 
neurons in virtually every function of the brain and as participants in the patophysiology 
of the dysfunctional or diseased brain. (37) 
 
2.1.1 THE NEURON 
The neuron (nerve cell) is the fundamental unit of the nervous system. When combined 
into networks, neurons allow the human body memory, emotion, and abstract thought as 
well as basic reflexes. The human brain contains an estimated one hundred billion 
neurons which relay, process, and store information. (34) 
Neurons have many different shapes and sizes. However, a typical neuron in a 
vertebrate (such as a human) consists of four major regions: a cell body, dendrites, an 
axon, and synaptic terminals. (34) 
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2.1.1.1 The cell body 
The cell body (soma) is the enlarged portion of a neuron that most closely resembles 
other cells. The entire neuron, like all other cells, is enclosed by a plasma membrane. 
This is a bilayer of phospholipid molecules, which acts as a barrier preventing the 
contents of the cell from mixing with those of the extracellular space. The plasma 
membrane is also an effective electrical insulator, hindering the diffusion of charged 
ions in and out of the cell. This is important, because signaling in nerve cells requires 
the controlled movement of ions across the plasma membrane, a process mediated by 
specialized proteins located in the membrane. (45) 
The cell body contains the nucleus (which contains the genetic material, DNA) and is 
the site of synthesis of virtually all neuronal proteins and membranes.  It also contains 
other organelles (for example, the mitochondria, the smooth and rough endoplasmic 
reticulum, the Golgiho complex, lysosomes) and it coordinates the metabolic activity of 
the neuron. (34, 47) In fact, because a great deal of energy is required to maintain the 
transmembrane ionic gradients that are essential for neuronal signaling, neurons tend to 
be particularly rich in mitochondria. There are also ribosomes, which are responsible for 
the synthesis of proteins destined for insertion into membranes, or for secretion. They 
are located on the membranous sacs of the rough endoplasmic reticulum. (45) 
 
2.1.1.2 The dendrites 
The dendrites, which branch out in treelike fashion from the cell body, are specialized 
to receive signals and transmit them toward the cell body. The single long axon carries 
signals away from the cell body. (34) 
 
2.1.1.3 The axons 
 
Structure of axons 
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Axons are essential for the functioning of the nervous system, which in humans, is 
composed of nearly 45% white matter. (24) 
Almost every neuron has a single axon, whose diameter varies from a micrometer in 
certain nerves of the human brain to a millimeter in the giant fiber of the squid. (47) 
The axon originates at a cone shaped thickening on the cell body called the axon 
hillock. It is often (but not always) unbranched until just before it terminates, but it may 
branch many times in its terminal region. The diameter of the axon remains more or less 
unchanged throughout its length. Its structure, like that of the dendrite, is formed and 
maintained by the cytoskeleton, cellular scaffolding that is present in all cells. (45) 
 
Action potentials 
Axons are specialized for the conduction of a particular type of electric impulse, called 
action potentials. These are propagated from the cell body down the axon to the 
synaptic terminals. (34) 
An action potential is a series of sudden changes in the voltage, or equivalently the 
electric potential, across the plasma membrane. When a neuron is in the resting 
(nonstimulated) state, the electric potential across the axonal membrane is 
approximately −60 mV (the inside negative relative to the outside); the magnitude of 
this resting potential is similar to that of the membrane potential in most non-neuronal 
cells. (47) 
When the membrane potential is less negative than the resting potential, the cell is said 
to be depolarized. As the depolarizing stimulus gets larger, a critical stimulus strength 
or threshold is reached. The level of the threshold varies from neuron to neuron, but it 
tends to be in the range 10-20 mV depolarized from the resting potential. Beyond the 
threshold, one observes a large change in membrane potential several milliseconds in 
duration. The membrane potential depolarizes very rapidly. (45) 
The depolarization of the membrane is followed by a rapid repolarisation, returning the 
membrane potential to the resting value. These characteristics distinguish an action 
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potential from other types of changes in electric potential across the plasma membrane 
and allow an action potential to move along an axon without diminution. (47) 
Only stimuli of sufficient importance result in information transfer via action potentials 
in the axon. Another important property of action potentials is that they are all-or-none 
events. The all-or-none law means that any stimulus large enough to produce an action 
potential produces the same size action potential, regardless of the stimulus strength. In 
other words, once the stimulus is above threshold, the amplitude of the response no 
longer reflects the amplitude of the stimulus. (45) 
The phenomenon of passive spread (as will be discussed in more details later), allows 
the propagation of action potential along the axon and the transfer of information over 
long distances within the neuron. 
Action potentials move rapidly, at speeds up to 100 meters per second. In humans, 
axons may be more than a meter long, yet it takes only a few milliseconds for an action 
potential to move along their length. A single axon in the central nervous system can 
synapse with many neurons and induce responses in all of them simultaneously. (47) 
 
Axonal transport 
The axon utilizes a process known as axonal transport for moving vesicles and other 
organelles to regions remote from the neuronal cell body. Proteins called molecular 
motors make use of energy released by hydrolysis of ATP to drive axonal transport (45) 
By a process called anterograde transport, vesicles or multiprotein particles are 
transported along microtubules down the length of the axon to the terminals, where they 
are inserted into the plasma membrane or other organelles. Axonal microtubules also 
are the tracks along which damaged membranes and organelles move up the axon 
toward the cell body; this process is called retrograde transport. (47) 
We have seen that cutting an axon, or interrupting transport in axon, produces a 
restructuring of the synaptic contacts made by that axon and others that innervate the 
same target. These same procedures can also produce changes in the presynaptic contact 
onto the cell whose axon has been cut. The loss of presynaptic terminals following 
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interruption of an axon has been observed in many different pathways (56). It appears, 
therefore, that the normal maintenance of synaptic endings may depend on factors 
available only from an intact postsynaptic cell. (45) 
 
Axonal regeneration in the CNS of mammals 
The capacity for injured neurons to regenerate axons and remake functional connections 
with target organs distinguishes the peripheral from the central nervous system. This 
unique characteristic of the peripheral nervous system stems from the ability of the 
Schwann cells as opposed to the inability of the oligodendrocytes in the central nervous 
system to support axonal regeneration. In consequence, return of function after 
peripheral nerve injuries contrasts with permanent deficits associated with central nerve 
injuries. (65) 
After a lesion develops, the CNS environment contains different cell types that could be 
involved in the expression of such inhibitory molecules: oligodendrocytes, astrocytes, 
activated microglia and fibroblasts. All of these cell types have now been shown to 
express or produce inhibitory factors that can influence axonal outgrowth. (41) 
There are several known myelin-derived proteins, which show axon growth-inhibitory 
properties limiting anatomical and functional recovery. Such molecules are myelin-
associated glycoprotein (MAG) (60, 84), oligodendrocyte-myelin glycoprotein (OMgp) 
(94), chondroitin sulphate proteoglycans (61), and the newly identified Nogo family 
(16i, 11). Current approaches strive to neutralize the inhibitory action of Nogo–A by 
administration of purified anti-Nogo-A-antibodies via miniosmotic, subcutaneously 
implanted pumps that deliver the antibody directly into the cerebrospinal fluid. An 
important future approach to neutralize the action of growth inhibitory molecules 
including the Nogo family, MAG, and OMgp is the administration of receptor 
antagonists and antibodies. (23, 46) 
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2.1.1.4 The synapses 
Synapses generally transmit signals in only one direction: an axon terminal from the 
presynaptic cell sends signals that are picked up by the postsynaptic cell. The 
postsynaptic neuron at certain synapses also sends signals to the presynaptic one. Such 
retrograde signals can be gases, such as nitric oxide and carbon monoxide, or peptide 
hormones. This type of signaling, which modifies the ability of the presynaptic cell to 
signal the postsynaptic one, is thought to be important in many types of learning. (47) 
There are two general types of synapse: the relatively rare electrical synapse, and the 
chemical synapse. Chemical and electrical synaptic transmission exists side by side in 
most nervous systems. 
 
The electrical synapses 
There are no morphological specializations that allow pre- and postsynaptic elements to 
be distinguished in this type of synapses. Indeed since signals can move in both 
directions through electrical synapses, each cell may be pre- or postsynaptic at different 
times. Electrical synapses are characterized by an area of very close apposition between 
the membranes of the pre- and postsynaptic cells. Within these membranes are found 
gap junctions. (45) 
The channels comprising a gap junction are large-diameter aqueous pores that extend 
from one cell, across the extracellular space, into an adjacent cell. These channels allow 
all inorganic ions and small organic molecules to diffuse freely from the interior of one 
cell into the interior of another cell. (74)  
Two important functional properties follow immediately from this mode of 
transmission. First, as referred to above, information transfer can be bidirectional. The 
second important functional consequence of this mechanism is that electrical synapses 
are fast. There is no delay analogous to that seen with chemical synaptic transmission. 
(45) 
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The discovery of gap junctional communication challenged the fundamental concept of 
classical cell theory, which states that individual cells are autonomous functional units. 
When cells are connected with their neighboring cells by gap junctions, the functional 
unit is no longer the individual cell of classical cell theory but rather the large aggregate 
of cells that are so joined, because the share so much of their cytoplasmatic contents. 
(74) 
 
Chemical synapses 
In this type of synapse, the axon terminal of the presynaptic cell contains vesicles filled 
with a particular neurotransmitter. The postsynaptic cell can be a dendrite or cell body 
of another neuron, a muscle or gland cell, or, rarely, even another axon. When an action 
potential in the presynaptic cell reaches an axon terminal, it induces a localized rise in 
the level of Ca2+ in the cytosol. This, in turn, causes some of the vesicles to fuse with 
the plasma membrane, releasing their contents into the synaptic cleft, the narrow space 
between the cells. The neurotransmitters diffuse across the synaptic cleft; it takes about 
0.5 milliseconds (ms) for them to bind to receptors on postsynaptic cells. 
Binding of the neurotransmitter triggers changes in the ion permeability of the 
postsynaptic plasma membrane, which, in turn, changes the membrane's electric 
potential at this point. If the postsynaptic cell is a neuron, this electric disturbance may 
be sufficient to induce an action potential. If the postsynaptic cell is a muscle, the 
change in membrane potential following binding of the neurotransmitter may induce 
contraction; if a gland cell, the neurotransmitter may induce hormone secretion. (47) 
 
Glia and synaptic transmition 
Glial cell processes envelop many synapses in the CNS and the PNS, often abutting the 
synaptic cleft. This close structural association suggests a physiological interaction 
between glial cells and neurons. Indeed, glial cells possess many neurotransmitter 
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receptors and respond actively to a variety of neurotransmitters and modulators. 
Activated glial cells, in turn, release chemical transmitters that stimulate postsynaptic 
neurons and modulate transmitter release from presynaptic terminals. (59) 
These close structural and physiological interactions have led to the suggestion that glial 
cells function as an active partner in synaptic transmission. The importance of glial cells 
in synaptic function has been emphasized by the coining of the term tripartite synapse to 
stress that the third element of the synapse, the glial cell, is an essential constituent in 
determining synaptic function, along with the pre- and postsynaptic neurons. (59) 
Few, if any, gap junctions are found between oligodendrocytes in white mater of the cat, 
although gap junctions are abundant between oligodendrocytes and astrocytes. Based on 
ultrastructural data, it is proposed that communication between oligodendrocytes is 
mediated by connections through the astrocyte syncytium. (75) However, gap junctions 
have been seen between purified rat oligodendrocytes, and physiological coupling can 
be demonstrated directly between oligodendrocytes in vitro and in situ. (74) 
Oligodendrocytes appear to be widely coupled by junctions that allow only weak 
electrical interaction, in accordance with the ultrastructural observation that 
interoligodendrocytic gap junctions are much less frequent than gap junctions between 
astrocytes. (75) 
 
2.1.2 OLIGODENDROCYTES 
 
2.1.2.1 Morphology and function of oligodendrocytes 
RioHortega (1928) is credited with first identifying oligodendrocytes as process-bearing 
cells by metal impregnation techniques. The oligodendrocyte is mainly a myelin 
forming cell, but there are also satellite oligodendrocytes that may not be directly 
connected to the myelin sheath. Satellite oligodendrocytes are perineuronal and may 
serve to regulate the microenvironment around neurons. (48) 
An oligodendrocyte extends many processes, each of which contacts and repeatedly 
envelopes a stretch of axon with subsequent condensation of this multispiral membrane-
forming myelin. On the same axon, adjacent myelin segments belong to different 
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oligodendrocytes. The number of processes that form myelin sheaths from a single 
oligodendrocyte varies according to the area of the CNS and possibly the species. (5) 
Rio Hortega classified oligodendrocytes in four categories, in relation to the number of 
their processes. According to their morphology and the size or thickness of the myelin 
sheath they form, Butt et al. also distinguish four types of myelinating oligodendrocytes, 
from small cells supporting the short, thin myelin sheaths of 15–30 small diameter 
axons (type I), through intermediate types (II and III), to the largest cells forming the 
long, thick myelin sheaths of one 1–3 large diameter axons. (5) 
These phenotypic differences determine the conduction properties of axons within 
oligodendrocyte units. The numbers and distributions of oligodendrocyte phenotypes 
are related to the age of myelination, and are likely to be determined by the competition 
for axon-derived and environmental factors. Key issues are how environmental, axonal, 
and genetic factors control the differentiation of oligodendrocyte phenotypes and how 
oligodendrocytes and myelin, in turn, determine axonal growth and integrity, as well as 
the periodicity of nodes of Ranvier (will be discussed later). (10) 
 
2.1.2.2 Types of oligodendrocyte cell death 
Oligodendrocyte cell death can follow necrotic, apoptotic, or hybrid pathways. In 
general, feature of necrotic cell death include loss of cell membrane integrity, rapid 
organelle swelling, mitochondrial failure, and energy depletion. Apoptotic features 
include nuclear condensation, intranucleosomal DNA cleavage, and membrane 
blebbing. In hybrid cell death, cells present features of both apoptosis and necrosis, 
which is hypothesized to result from the initiation of apoptosis followed by energy 
failure and necrotic mitochondrial and plasma membrane rupture. (53) 
In vitro and in vivo experiments have shown that oligodendrocytes are very vulnerable 
to hypoxic and ischemic insults. What triggers the death of oligodendrocytes in cerebral 
ischemia remains to be elucidated. (83) 
Recent evidence indicates that excitotoxic mechanisms can also contribute to 
oligodendrocyte injury. Initial cell culture studies defining oligodendrocyte sensitivity 
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to glutamate demonstrated that glutamate-mediated cell death of oligodendrocyte 
lineage cells is elicited by activation of either AMPA or kainate receptors, but not by 
NMDA or metabotropic glutamate receptors, in a dose-dependent manner. (58) 
Myelin damage in the CNS and PNS is frequently associated with immune and 
inflammatory disorders. Oligodendrocyte and Schwann cell injury may be mediated by 
cytokines, antibody, complement, or specific activation of death receptors. Immune 
cells, microglia, and reactive astrocytes are all sources of cytokines in the damaged 
CNS. (58) 
 
2.1.2.3 Oligodendrocytes and myelin 
The myelin sheath around most axons constitutes the most abundant membrane 
structure in the vertebrate nervous system. Its unique composition (richness in lipids and 
low water content allowing the electrical insulation of axons) and its unique segmental 
structure responsible for the salutatory conduction of nerve impulses allow the myelin 
sheath to support the fast nerve conduction in many fibers in the vertebrate system. 
(1M) The sheath is formed by OCs in CNS axons and by Schwann cells in the PNS. A 
single Schwann cell myelinates only one axon, in contrast to oligodendrocytes, which 
myelinate a family of axons, with estimates ranging from 1-2 to nearly 100 axons per 
family (45) 
The importance of this myelin covering to normal nervous system function is made 
painfully obvious in individuals with demyelinating diseases in which the myelin 
covering of the axons is destroyed. Among these diseases is multiple sclerosis, a 
demyelinating disease of the central nervous system that can have devasting 
consequences, including visual, sensory, and motor disturbances. (34). 
 
Structure and composition of myelin 
 When a myelinated axon is examined in cross section with an electron microscope, the 
axon is found to be surrounded by concentric circles of alternating dark and light bands. 
This structure arises by the tight wrapping of the membrane of the oligodendrocyte or 
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Schwann cell around the axon during development. The cytoplasm of the glial cell is 
gradually squeezed out of this region as the cell wraps at around the axon, so that the 
concentric circles represent layers of closely apposed glial plasma membrane. (45) 
In contrast to most plasma membranes, myelin is a lipid-rich membrane (lipids 
constitute 70% of dry myelin weight) that is highly enriched in glycosphingolipids and 
cholesterol. There is also an unusually high proportion of ethanolamine 
phosphoglycerides in the plasmalogen form, which accounts for one-third of the 
phospholipids. Myelin contains a relatively simple array of proteins, myelin basic 
protein (MBP) and the proteolipid proteins (PLP/DM20) being the two major CNS 
myelin proteins. (57). 
During the active phase of myelination, each oligodendrocyte must produce as much as 
≈5-50x103 µm2 of myelin membrane surface area per day. (72) 
 
Saltatory conduction 
The speed of action potential propagation along the axon is determined in part by 
myelination. This comes about, because the myelin sheath, which consists of a large 
number of layers of glial plasma membrane wrapped about the axon, acts as an 
excellent electrical insulator. The high electrical resistance and low capacitance of 
myelin prevents current loss during action potential conduction. (35, 45) 
The myelin is punctuated by nodes of Ranvier. The internode distances ranging from 
less than 100µ (small-diameter fibers) to slightly over 1mm (larger-diameter fibers) 
optimize conduction velocity. Because of their specialization, both structural and 
molecular, myelinated fibers can conduct action potentials rapidly in a discontinuous or 
saltatory manner, unlike nonmyelinated fibers, which usually conduct impulses in a 
slower, continuous manner. (35) 
As already mentioned, the saltatory conduction (from the Latin saltare, meaning to 
leap) permits conduction at speeds many time faster than in nonmyelinated axons of the 
same diameter. The passive spread of the action potential depolarization along the 
myelinated portion of the axon can bring the adjacent node above threshold, allowing 
the action potential to „jump“ along the axon from node to node. 
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Myelinated axon membrane is highly specialized, with several types of voltage-
sensitive ion channels and other proteins distributed in a spatially heterogeneous 
manner. The sodium channels are not spread evenly throughout the axonal plasma 
membrane, but are sparse in the intervening membrane under myelin. (45) At the nodes 
of Ranvier, Na+ channels cluster in high density in the axon membrane. Together these 
factors allow the action potential to jump from node to node, achieving conduction with 
the minimum use of ion channels or energy-consuming pumps. 
The high density of nodal Na+ channels and the paucity of these channels in the axon 
membrane under the myelin, combined with the presence of fast K+ channels in the axon 
membrane under the paranodal myelin, have important implications for axonal 
pathophysiology. (35) 
The need for rapid conduction of the nerve impulse serves as a driving force that can 
determine and increase animal size. For an axon without myelin, the speed of impulse 
conduction is proportional to the diameter1/2.  Therefore, in order to achieve a faster rate 
of conduction, species that lack myelin have to substantially enlarge their axons. (35) 
 
Myelin biogenesis 
Myelination is a developmentally regulated event that begins postnatally in the rat and 
mouse brain and within the third fetal trimester in the human spinal cord. (12) In those 
species in which birth occurs before myelination, the newborns are extremely limited in 
motor performance, and in fact are quite helpless until myelination is complete. (45) 
Since the ensheathment of the axons must occur at the appropriate time of neuronal 
development, reciprocal communication between neurons and oligodendrocytes is 
essential to coordinate myelin biogenesis. (7) Neurons control the development of 
oligodendrocytes by regulating the proliferation, differentiation and survival of 
oligodendrocytes. (4) The signals are important to match the number of 
oligodendrocytes to the axonal surface requiring myelination. Furthermore, the timing 
of myelination is crucial because the ensheathment of axons must not occur before 
neurons signal to oligodendrocytes. In turn, signals from oligodendrocytes to neurons 
are necessary to cluster multiprotein complexes in the axonal membrane into distinct 
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subdomains at the nodes of Ranvier. (57) Moreover, the axonal cytoskeleton and the 
rate of vesicular transport along the axons are modified by oligodendrocytes. (20) 
Myelination of the axonal tracts of the CNS by oligodendrocytes takes place when 
oligodendrocytes have differentiated from oligodendrocyte precursor cells (OPCs). 
OPCs arise from the neuroepithelium of ventricular/subventricular zone of the brain and 
migrate from this region into the developing white matter until they reach the 
appropriate axons. After OPCs have arrived at their final target, they exit the cell cycle, 
become non-migratory and differentiate into myelin forming oligodendrocytes. To 
ensure full and timely myelination of all axonal tracts, the timing of OPC differentiation 
must be tightly controlled by their target cells. (57) 
Many studies now point to the importance of extrinsic neuron-derived signaling 
molecules at multiple stages of oligodendrocyte development. (13M) these extrinsic 
signals serve two major purposes. They help to control the proper timing of OPC 
differentiation to ensure myelination at the appropriate time and place, and they control 
and match the number of oligodendrocytes to the axonal surface area requiring 
myelination. Several growth factors and trophic factors, such as PDGF-A, FGF-2, IGF-
1, NT-3 and CNTF, have been shown to regulate oligodendrocyte development. (57) 
The next event after differentiation of OPCs is the formation of myelin. Myelination is a 
multi-step process requiring precise coordination of several different signals. The 
following steps can be distinguished:  
 Recognition of and adhesion of the oligodendrocytes to the appropriate axon 
 Synthesis and transport of myelin components to the axon 
 The wrapping of the myelin membrane around the axons 
 The compaction of the myelin sheath.  (57) 
The crucial mechanism by which an oligodendrocyte ensheaths axons with a spiral wrap 
that finally compacts to form the myelin sheath is a fundamental aspect of both 
myelination and remyelination about which little is known. (25) 
 
Demyelination 
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When the myelin is damaged, the density of action current falls due to capacitative and 
resistive shunting. If the safety factor (the ratio between current available to stimulate a 
node of Ranvier and current required to stimulate the node) is reduced, but is still 
greater than 1, the charging time for the nodal membrane will be increased so that it will 
take longer than normal for the axon to reach threshold, and conduction will continue 
but conduction velocity will be reduced. In more severely demyelinated axons, the 
safety factor can fall under 1, so that threshold will not be reached, hence conduction 
will fail.  
In addition to capacitative current loss through injured myelin sheaths, conduction in 
focally demyelinated axons can fail due to mismatch. The low density of Na+ channels 
in the demyelinated axon membrane also contributes to conduction block. Moreover, 
fast K+ channels are unmasked after demyelination, and due to that they impede action 
potential electrogenesis. (57)  
The pathogenesis of demyelination after injury may be due to loss of mature 
oligodendrocytes or may be secondary to other processes such as microglial activation 
or loss of trophic support after axonal degeneration. Some evidence suggests that 
insulin-like growth factor-1 (IGF-1) may reduce primary and secondary postischemic 
white matter injury. IGF-1 promotes the proliferation and differentiation of 
oligodendroglia and up-regulates myelin production in vitro. IGF-1 has broad, receptor-
mediated antiapoptotic effects in vitro and in vivo and specifically inhibits the apoptotic 
loss of oligodendrocytes associated with cytokine toxicity and metabolic insults. 
Experimental demyelination is associated with distinctive patterns of induction of IGF-1 
in astrocytes and the IGF-1 receptor in oligodendrocytes during subsequent regeneration 
(33), suggesting that endogenous IGF-1 may play a key role in remyelination.  
Currently, there is little information on the role of IGF-1 in oligodendrocyte survival or 
cerebral demyelination after hypoxic–ischemic injury in the developing brain. It has 
been shown that postischemic administration of IGF-1 can protect cortical and striatal 
neurons from ischemic injury in the near-term fetal sheep. (32) 
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2.2 THE CEREBRAL CORTEX  
The cerebral cortex is well endowed with neurons, neuroglia, nerve fibers, and a rich 
vascular supply. The arrangement of the three types of neurons that populate the cortex 
- pyramidal cells, stellate neurons, and fusiform neurons - permit the classification of 
the cortex into three types: the archicortex (allocortex), mesocortex (juxtallocortex), and 
neocortex (isocortex). 
The archicortex, phylogenetically the oldest region, is composed of only three layers 
and is located in the limbic system. The mesocortex, phylogenetically younger, is 
composed of three to six layers, and is located predominantly in the insula and cingulate 
gyrus. The neocortex, phylogenetically the youngest region of the cerebral cortex, is 
composed of six layers and comprises the bulk of the cerebral cortex. (31) 
 
2.2.1 THE NEOCORTEX 
The neocortex is that part of the brain which makes up the outer 2 to 4 mm of the 
cerebral hemispheres. It is the ‘gray matter’ of the brain lying atop the cerebral ‘white 
matter’ composed of myelinated axons that interconnect different regions of the brain. 
(96) The corpus callosum connects the neocortex of the right hemisphere with that of 
the left. (31) 
All the higher-level psycho-physical functions sensory perception, object- and event-
representation, planning, and decision making are believed to take as their biological 
substrate the activities of interconnected and distributed networks of neurons in the 
neocortex. (96) 
Glia and non-neuroglia elements make up almost 70% of the volume of the neocortex. 
Of the remainder, 22% consists of axons and dendrites, with the body (soma) of the 
neuron comprising only 8%. (76) 
The neocortex can vary in thickness and topology. In comparison of the human and rat 
cortices we can see a definite difference in shape. The wave like nature of the cortex we 
see in the human brain is not as apparent in the brain of the rat. (9)  
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The cortex structure is highly folded with many grooves (called ‘sulci’). This folded 
arrangement allows for a far greater volume of cortical matter to be contained within a 
given-sized brain cavity than would be possible if the cortex were laid out in a ‘sheet’ 
directly beneath the skull. The sulci provide convenient ‘landmarks’ for helping 
anatomists to classify different regions of the cerebral cortex. (96) The defined areas of 
the cortex include the motor cortex, the sensory cortex and the associative cortex. All 
three of these areas are responsible for functions of the organisms ranging from control 
of body movement to sound recognition to mental processing. (9) 
 
2.2.1.1 Cell types and layers of the neocortex 
As was said, the cortex depth can be various depending on the animal and consists of 
approximately 6 layers. The layers can be distinguished by the horizontal nature of the 
cell geometries and/or densities that are particular to each layer. (9) 
Layer I, the outermost layer, is often called the molecular layer or, somewhat 
misleadingly, the ‘acellular’ layer. (96) Layer I, however, actually contains few neurons 
and is mostly made up of tangentially running axons and horizontally running 
bifurcating apical dendrites received from the pyramidal cells of the lower layers. (76) 
Layer II, the external granular cell layer, contains a mix of small pyramidal cells and 
some inhibitory neurons, mainly bipolar cells and double bouquet cells. It also contains 
apical dendrites from pyramidal cells whose cell bodies are found in layers V and VI.  
Layer III contains a variety of cells essentially consisting of almost all cell types found 
in the neocortex except the excitatory spiny stellate cell and cells found exclusively in 
layer I (the Cajal-Retzius cell and small unclassified inhibitory cells). The majority of 
cells in layer III are small pyramidal cells. (96) 
Layer IV, the Internal Granular Layer, has a granular appearance and consists of small 
pyramidal, granule, and stellate (star shaped) cells and receives massive axonal 
projections from the thalamus. These neurons are predominantly local circuit, and 
project to adjacent columns and layers. That is, upon receiving and analyzing thalamic 
input, the neurons of layer IV transfer this data to adjacent neurons for additional 
 28 
analysis. Because the primary, secondary and association sensory areas receive 
considerable thalamic input, layer IV is relatively thick- except in the motor cortex. (76) 
Layer V is composed mainly of large pyramidal cells with a smaller population of 
inhibitory cells. Axons and possibly basal dendrites of non-spiny bipolar cells (which 
are inhibitory) are also found in layer V. Chandelier cells, which are inhibitory cells that 
make synaptic connections only to the axons protruding from other neurons, are often 
found in layer V. (96) The pyramidal neurons of layer V are long distance neurons, and 
give rise to descending axons which form the corticospinal, pyramidal, corticobulbar, 
corticopontine, and corticorubral brainstem pathways which establish contact with 
cranial nerve and sensory and spinal motor neurons. (76) 
Layer VI is a heterogeneous layer of various neurons that blends gradually into the 
white matter. Most of the cells in layer VI are large pyramidal cells that project their 
axons back to the thalamus. Layer VI also contains a class of inhibitory neurons called 
Martinotti cells whose axonal outputs make long projections across all layers of the 
neocortex. After layer IV, layer VI is the next principal target of thalamic inputs to the 
neocortex. (96) 
 
2.3 THE HIPPOCAMPAL FORMATION 
The hippocampal formation is a prominent component of the rat nervous system that 
has attracted the attention of neuroanatomists since the beginning of formal study of the 
nervous system. (1) The hippocampus is perhaps the most studied structure in the brain. 
Together with the adjacent amygdala, it forms the central axis of the Limbic System. 
(See att. 1) 
 
2.3.1 ANATOMY AND CONNECTIONS OF THE HIPPOCAMPAL 
FORMATION 
The term hippocampal formation is commonly used to refer to the hippocampus proper 
and dentate gyrus, although it has to be acknowledged that the term is sometimes also 
used to include the subicular complex and sometimes even the entorhinal cortex. (1) 
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Ramón y Cajal (1893) divided the hippocampus into two components: dentate gyrus 
and Ammons horn, and Ammons horn was subdivided in an “upper” (also labeled regio 
superior) and a “lower” region (regio inferior). This terminology has largely been 
displaced by the terminology that was introduced by Lorente de Nó, i.e., dentate gyrus 
and three subfields (CA1 [regio superior], and CA2 and CA3 [regio inferior]). But, 
especially in human and monkey literature the terms regio superior and regio inferior, 
and CA4 for hilus, are still used. (39) 
 
2.3.1.1 Dentate gyrus 
The major input is from enthorhinal cortex via the so-called perforant path. The 
entorhinal to dentate gyrus projection is not reciprocated. (1) 
The dentate gyrus consists of three layers: the molecular layer, the granule cell layer, 
and the polymorph zone. The principal cells of the dentate gyrus are the granule cells, 
whose dendritic tree is confined to stratum moleculare. The hilus, or polymorph zone of 
the dentate gyrus, is located below the granule cell layer and is bordered by CA3. The 
principal, and most abundant, cell types of the hilus are the mossy and basket cells. But 
many other interneurons are present in the dentate gyrus and hilus and these have 
projections that, in general, are related to the type of interneuron, e.g., basket cells 
primarily innervate the cell body layer. The granule cells of the dentate gyrus are 
considered to be the first stage of the trisynaptic loop. (1, 39) 
 
2.3.1.2. Hippocampus proper 
The axons from the granule cells (the mossy fibers) leave the hilar region and synapse 
on the proximal dendrites of the CA3 pyramidal cells, and this represents the second 
stage of the trisynaptic loop. It should be noted that the mossy fibers also terminate 
densely on the mossy and basket cells of the hilus. The basal dendrites of the CA3, 
CA2, and CA1 pyramidal cells ramify in stratum oriens above the pyramidal cell layer, 
whereas the apical dendrites are present below the pyramidal cell layer. The area where 
the shafts of the apical dendrites are located (with little branching) is called stratum 
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radiatum, and the apical dendrites branch extensively in stratum lacunosum-moleculare. 
(39) 
In CA3 there is an additional layer called stratum lucidum located between the 
pyramidal cell layer and the stratum radiatum, within which the mossy fibers course and 
terminate. The axons of CA3 pyramidal cells project densely to CA1, as originally 
described by Schaffer (1892), but they also give rise to relatively dense axonal 
arborisations within CA3. The projection to CA1 represents the third stage of the 
trisynaptic loop. (39) 
 
2.3.1.3. Subiculum 
The axons from the CA1 pyramidal cells synapse on the dendrites of the subicular 
pyramidal cells and this can be seen to represent the “fourth” stage of the trisynaptic 
loop. Unlike the pyramidal cells of CA3 and CA1, the pyramidal cells of the subiculum 
are not arranged in one layer, they are more dispersed and show differences between the 
deeper and more superficial neurons. (39) 
 
The subiculum has a range of electrophysiological and functional properties which are 
quite distinct from its input areas; given the widespread set of cortical and subcortical 
areas with which it interacts, it is able to influence activity in quite disparate brain 
regions. The rules governing plasticity of synaptic transmission in the hippocampal-
subicular axis are poorly understood; this axis appears to share some properties in 
common with the hippocampus proper, but behaves quite differently in other respects. 
Equally, its functional properties are not well understood; it plays an important but ill-
defined role in spatial navigation, mnemonic processing and control of the response to 
stress. (64) 
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2.3.1.4 The trisynaptic loop 
The hippocampus, when cut transverse to its longitudinal (septal-temporal) axis, 
exhibits a strong afferent set of three connected pathways known as the "trisynaptic" 
circuit or loop. (97) 
 
Figure 1. The trisynaptic loop of the hippocampus. The filled triangles represent the 
pyramidal cell layer (CA1 and CA3) and the filled circles represent the granular cell 
layer of the dentate gyrus. Abbreviations: EC = entorhinal cortex; DG = dentate gyrus; 
pp = perforant pathway; mf = mossy fibers; sc = Schaffer collaterals; ff = fimbria 
fornix. (1) 
 
Afferents from the entorhinal cortex synapse onto granule cells, the principal cells of 
the dentate gyrus, via the perforant-path. The granule cells send their axons (mossy 
fibers) to the proximal dendrites of CA3 pyramidal cells. In turn, these cells project to 
the dendritic regions of CA1 pyramidal cells via Schaffer collaterals. The principle 
extrinsic projections arise from the CA1 pyramidal cells and terminate in the entorhinal 
cortex and subiculum, completing the cortico-hippocampo-cortical loop. (95) 
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2.4. STROKE 
 
2.4.1 INTRODUCTION TO STROKE 
A stroke occurs when the blood supply to part of the brain is suddenly interrupted or 
when a blood vessel in the brain bursts, spilling blood into the spaces surrounding brain 
cells. Brain cells die when they no longer receive oxygen and nutrients from the blood 
or there is sudden bleeding into or around the brain. The symptoms of a stroke include 
sudden numbness or weakness, especially on one side of the body; sudden confusion or 
trouble speaking or understanding speech; sudden trouble seeing in one or both eyes; 
sudden trouble with walking, dizziness, or loss of balance or coordination; or sudden 
severe headache with no known cause. There are two forms of stroke: ischemic - 
blockage of a blood vessel supplying the brain, and hemorrhagic - bleeding into or 
around the brain. (62) 
 
2.4.2 STROKE STATISTICS 
Stroke is the leading cause of disability in the United States. Approximately 700,000 
people experience a stroke each year. There are an estimated 5 million stroke survivors 
living in the 
United States. Stroke places a financial burden on our society with the projected cost of 
stroke care in 2007 approaching 62 billion dollars. (77) 
The most significant physical impact on stroke survivors is long term disability. In the 
stroke survivor population, 50% have some level of hemiparesis, 30% are unable to 
walk without some assistance and 20% are dependent in activities of daily living. (77) 
Men have strokes at a younger age than women; therefore the age adjusted incidence of 
stroke is 1.25 times greater for men than for women. (2) The risk of stroke for blacks is 
almost double that of Whites, and Hispanics have a greater incidence of hemorrhagic 
stroke at a younger age. Most strokes (88%) are ischemic events, while other etiologies 
include intracerebral haemorrhage (9%) and subarachnoid haemorrhage (3%). 
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Stroke is a life changing event that affects not only the person who may be disabled, but 
the entire family and other caregivers as well. Utility analyses show that a major stroke 
is viewed by more than half of those at risk as being worse than death. (80) 
 
2.4.3 RISK FACTORS OF STROKE 
The major or more common risk factors for cerebral ischemia and infarction include 
family history, hypertension, smoking tobacco, diabetes mellitus, higher body mass 
index, and other risk factors for the development of atherosclerosis such as 
hypercholesterolemia. 
Smoking increases the risk of a stroke due to either arterial wall damage and 
atherosclerosis or formation and rupture of aneurysms. (69) Virtually every 
multivariable assessment of stroke risk factors (eg., Framingham, Cardiovascular Health 
Study, and the Honolulu Heart Study) has identified cigarette smoking as a potent risk 
factor for ischemic stroke associated with an approximate doubling of ischemic stroke 
risk (after adjustment for other risk factors). There is growing acceptance that exposure 
to environmental tobacco smoke (passive cigarette smoke) is a risk factor for heart 
disease. Several studies suggest that environmental tobacco smoke is also a substantial 
risk factor for stroke, with a risk approaching the doubling found for active smoking. 
(30, 101) 
Cardiac risk factors of stroke include atrial fibrillation and a recent myocardial 
infarction. (69) Other types of cardiac disease that can contribute to the risk of 
thromboembolic stroke include dilated cardiomyopathy, valvular heart disease (eg. 
mitral valve prolapse, endocarditis, prosthetic cardiac valves), and intracardiac 
congenital defects (eg. patent foramen ovale, atrial septal defect, atrial septal aneurysm). 
(30) 
The risk of hemorrhagic stroke is increased in persons of Asiatic or African descent. 
(69) Racial and ethnic effects on disease risk can be difficult to consider separately. 
African Americans (79, 99, 8) have higher stroke incidence and mortality rates as 
compared with European Americans. In the Atherosclerosis Risk in Communities 
Study, blacks had an incidence of stroke 38% higher than that of whites. (78) Possible 
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reasons for the higher incidence and mortality rate of strokes in blacks include a higher 
prevalence of hypertension, obesity, and diabetes within the black population. (27) 
Epidemiological studies have shown an increase in stroke incidence among self-
identified Hispanic racial-ethnic populations. (79, 26) Incidence rates are also relatively 
higher among some Asian groups. (86) 
Evidence of a prior TIA also increases the risk of a stroke. Additionally, the risk of 
having a stroke increases with age. (43) The use of hormonal contraceptives can also 
increase the risk of cerebral ischemia or infarction.  
 Other risk factors include hypertension, trauma, advanced age, heavy alcohol 
consumption, and cocaine and amphetamine abuse. (2) 
A sedentary lifestyle is associated with an increased risk of stroke. The beneficial 
effects of physical activity have also been documented for stroke. (30) 
The protective effect of physical activity may be partly mediated through its role in 
reducing blood pressure and controlling other risk factors for cardiovascular disease, 
diabetes, and increased body weight. Other biological mechanisms have also been 
associated with physical activity, including reductions in plasma fibrinogen and platelet 
activity and elevations in plasma tissue plasminogen activator activity and HDL 
concentrations. (30) 
 
2.4.4 PATOPHYSIOLOGY OF FOCAL CEREBRAL ISCHEMIA 
 
2.4.4.1 Mechanisms of ischemic injury 
Early observations on the mechanisms of ischemic injury focused on relatively simple 
biochemical and physiological changes which were known to result from interruption of 
circulation. Examples of these changes are: loss of high-energy compounds, acidosis 
due to anaerobic generation of lactate, and no reflow due to swelling of astrocytes with 
compression of brain capillaries. Subsequent research has shown the problem to be far 
more complex than was previously thought, involving the action and interaction of 
many factors. (15) 
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2.4.4.2 Biochemical events 
Within 20 seconds of interruption of blood flow to the mammalian brain under 
conditions of normothermia, the EEG disappears, probably as a result of the failure of 
high-energy metabolism. Within 5 minutes, high-energy phosphate levels have virtually 
disappeared (ATP depletion). (15) ATP is required for maintaining ionic gradients. The 
disruption of ionic gradients in neurons and glial cells is characterised by influx of Na+ 
and Ca2+, efflux of K+ from the cells and cellular depolarization. Somatodendritic and 
presynaptic voltage-dependent Ca2+-channels become activated and excitatory amino 
acids (eg. glutamate) are released to extracellular space, which further contributes to 
influx of Ca2+ into the cells directly through NMDA receptor and some AMPA 
receptors or indirectly through metabotropic glutamate receptors. Energy-dependent 
removal of excess glutamate from the extracellular space also becomes impaired. (17) 
Glutamate-mediated overactivation leads to opening of channels for monovalent ions 
resulting in influx of Na+ and Cl-. Water follows passively contributing to cell swelling 
and development of edema. (3) 
 
 
2.4.4.3 Excitotoxins 
A rapidly growing body of evidence indicates that excitatory neurotransmitters, which 
are released during ischemia, play an important role in the etiology of neuronal 
ischemic injury .The mechanisms by which excitotoxins cause cell injury is not yet fully 
understood. As already mentioned, it is known that they facilitate calcium entry into 
neurons. However, these agents are neurotoxic even in cell culture where the medium is 
calcium free. Those areas of the brain which show the most "selective vulnerability" to 
ischemia, such as the neocortex and hippocampus, are richly endowed with excitatory 
AMPA (alpha-amino-hydroxy-5-methyl-4-isoxazole proprionic acid) and NMDA (N-
methyl-d-aspartate receptors). (15) 
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2.4.4.4 Free radicals 
Increase in intracellular Ca2+ causes mitochondrial Ca2+ overload leading to a leakage of 
mitochondrial membrane, cessation of already compromised ATP production, and burst 
of oxygen free radicals (42). Oxygen free radicals contribute to membrane lipid 
peroxidation, damage to DNA and proteins, and production of inflammatory mediators. 
(38) 
 
2.4.4.5 Lactic acidosis 
While it is clearly not the sole or even the major source of injury in ischemia, lactic 
acidosis does apparently contribute to the pathophysiology of ischemia. It has been 
shown, for instance, that lactate levels above a threshold of 18 - 25 micromol/g result in 
currently irreversible neuronal injury. (15) 
Decrease in pH as a consequence of lactic acidosis has been shown to injure and 
inactivate mitochondria. Lactic acid degradation of NADH (which is needed for ATP 
synthesis) may also interfere with adequate recovery of ATP levels post ischemically. 
Lactic acid can also increase iron decompartmentalization, thus increasing the amount 
of free-radical mediated injury. (15) 
 
2.4.4.6 Histological ultrastructural changes 
Ischemic changes in cell architecture begin almost as rapidly as ischemic changes in 
biochemistry. Within seconds of the onset of cerebral ischemia, brain interstitial space 
almost completely disappears. Loss of interstitial space is a consequence of cell 
swelling secondary to sodium influx and failure of membrane ionic regulation. There 
have been several studies of the ultrastructural alterations associated with prolonged 
global cerebral ischemia in the rat. (15)  
The hemodynamic, ionic and metabolic changes do not affect the ischemic territory 
homogenously. In the centre of the ischemic territory, core, the CBF is below 10% of 
normal. This area is destined to die and the cells are killed rapidly. Between the core 
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and normal brain tissue lies penumbra, an area with reduced CBF (20-60% of normal) 
containing functionally depressed but viable cells with maintained ionic homeostasis. If 
blood flow in this area further decreases below the critical level or energy demand is 
exceeded, the infarct area will expand. Ischemic penumbra is potentially salvageable by 
pharmacological intervention. (38) 
 
2.4.5 CLINICAL PRESENTATION  
Regardless of the etiology, the clinical presentation of symptoms in a cerebral 
ischemic/infarction event depend upon:  
• the location of the vessels 
• the presence of collateral circulation.  
However, embolic strokes have a greater risk of subsequent bleeding into the infarcted 
area than thrombotic strokes. (69) 
Lacunar infarcts:  
These are small cavity infarcts (usually <15 mm wide) are usually associated with 
hypertension. They can be either silent with no associated clinical symptoms or present 
with very obvious symptoms. The most common symptoms seen with lacunar infarcts 
are either pure motor deficits or pure sensory deficits. (55) 
The middle cerebral artery:  
Complete occlusion of the middle cerebral artery results in loss of movement and 
sensation on the contralateral or opposite side of the infarction. However, there may be 
a gaze preference to the ipsilateral or same side as the injury. If this is the categorical 
hemisphere, there is also a global aphasia. (69) If it is the representational hemisphere, 
there is a neglect syndrome, or forgetting that there are two sides of the body. Partial 
occlusion of the middle cerebral artery could include weakness of a hand or arm, facial 
weakness, and partial aphasia. (55) 
The posterior cerebral artery:  
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There are 2 syndromes observed with occlusion of the posterior cerebral artery: P1 and 
P2. The P1 syndrome includes the midbrain, subthalamic, and thalamic regions of the 
brain. The symptoms include a third-nerve palsy with weakness and ataxia. Extensive 
infarction in this area can result in coma, unreactive pupils, and decerebrate rigidity. 
The P2 syndrome results in injury to the medial temporal and occipital lobes. This 
results in memory loss, disturbances, or loss of vision on the contralateral or opposite 
side of the infarct. In some individuals, visual disturbances can produce hallucinations. 
The basilar artery:  
The clinical presentation seen with occlusion of the basilar artery includes the “locked-
in” state of preserved consciousness with total quadriplegia. A TIA in this area may 
produce dizziness or a feeling of light-headedness. 
Superior cerebellar artery:  
Occlusion of this vessel causes cerebellar ataxia, partial deafness, nausea, vomiting, and 
loss of pain and temperature sensation on the opposite extremities. 
Anterior inferior cerebellar artery:  
The symptoms seen with occlusion of this vessel include ipsilateral deafness, facial 
weakness, and vertigo. (69) 
 
2.4.6 THERAPEUTIC STRATEGIES  
Recovery from ischemic stroke is quite variable but typically follows a time course in 
which most improvement occurs over 1-6 months. To the extent that recovery occurs, 
function appears to be redistributed to parallel pathways or to new alternate pathways, 
or both. For example, partial recovery from the contralateral hemiparesis associated 
with a stroke involving the primary motor cortex sometimes involves activation of 
regions in the opposite, undamaged hemisphere. (73, 85, 22) In other cases, activation 
of regions ipsilateral to the stroke occurs as new neurons are recruited to perform 
specific tasks. (85, 73, 22) Similar shifts have been demonstrated during recovery in 
rodent models. (16) 
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Physicians have a wide range of therapies to choose from when determining a stroke 
patient's best therapeutic plan. The type of stroke therapy a patient should receive 
depends upon the stage of disease. Generally there are three treatment stages for stroke: 
prevention, therapy immediately after stroke, and post-stroke rehabilitation. (62) 
 
2.4.6.1 New strategies 
Multiple novel strategies to reduce ischemic stroke burden are currently being 
investigated. It is expected that many of these strategies will be incorporated into our 
growing arsenal of stroke therapies and will allow us to reduce stroke-related mortality 
and morbidity. Multimodal combinations of novel lytic agents with mechanical 
reperfusion devices and stents and their further combinations with newer effective 
neuroprotectants may increase the therapeutic effects even further. Another approach to 
improve stroke outcome is to enhance late healing processes in the brain by cell and 
growth factor therapy. (44) 
 
Prestroke 
• Prophylactic neuroprotection for high-risk patients? 
Minutes to hours after stroke 
• Acute reperfusion therapies 
• Intravenous thrombolysis 
• Intra-arterial thrombolysis 
• Combined intravenous/intra-arterial thrombolysis 
• Mechanical reperfusion techniques 
Minutes, hours, or days after stroke 
• Neuroprotective therapy: chemotherapy cocktail of agents targeting different aspects of the 
ischemic cascade, perhaps administered sequentially at various time points after stroke 
(Antinecrotic,Antiadhesion/anti-inflammatory agents, Antiapoptotic agents) 
• Combined thrombolysis and neuroprotective therapy 
• Tight control of glucose, perhaps insulin administration 
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• Tight control of temperature, perhaps antipyretic administration, perhaps hypothermia 
Days, weeks, or months after stroke 
• Restorative treatments targeting specific deficits, eg., gait retraining, arm function 
• Pharmacotherapy coupled closely with rehabilitation (rehabilitation pharmacology)? 
• Growth factors coupled with rehabilitation? 
• Stem cell therapy coupled with rehabilitation? 
• Gene therapy? 
Ongoing 
• Avoidance of "detrimental" drugs 
• Secondary stroke prevention therapies, including combination antithrombotic agents 
 
 
Figure 2. Possible Stroke Treatment Options for the Future: Evolving Time Windows 
and Combination Therapy Approaches (28) 
 
 
Cell-mediated strategies 
Recent studies have highlighted the enormous potential of cell transplantation therapy 
for stroke. A variety of cell types derived from humans have been tested in experimental 
stroke models. Cell transplantation therapy for stroke holds great promise. (6) 
Cell-mediated strategies seek to partially restore the neural controls for complex 
cognitive, sensory, or motor functions. Cellular therapies, then, and perhaps other types 
of biologic and pharmacological interventions, could serve as adjuncts to the 
neurorehabilitation program of highly impaired subjects. Therapeutic cells may be 
capable of enhancing fundamental mechanisms for learning within circuits that they 
reconstruct or modulate, as well as by inducing, delivering, or extending in time peri-
infarct and more distant molecular signals for neurogenesis, cell differentiation, axonal 
and dendritic sprouting, network connectivity, and long-term potentiation. These gene-
induced, biochemical, physiological, and morphological modulations may be especially 
important for optimizing the function of spared pathways. (18) 
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White matter lesions may disrupt association, commissural, fascicular, and other 
projection fibers. If demyelination exists among spared axons, a remyelination strategy 
with stem cells or oligodendrocyte precursors to rescue axons becomes of interest. (18) 
Cellular transplants could modulate the sprouting of spared axons and the regeneration 
of disrupted axons by providing neurotrophins or acting on axon growth cone inhibitors, 
such as Nogo-A. (68) Cells with or without gene modifications for producing trophic or 
tropic substances could be placed into the perilesional or distal milieu to augment axon 
growth through white matter. The complexity of long distance axonal regeneration is 
formidable, however. The architectural barriers and the balance of pro-growth and 
inhibitory molecules in the milieu must be managed to guide axons through white 
matter to their targets. Axon extension beyond the lesion site has been accomplished in 
select experimental conditions in animal models, however. (13, 87) 
 
2.4.6.2 Stroke rehabilitation 
Rehabilitation plays a key role in improving outcome from stroke. Rehabilitation occurs 
in multiple physical domains. Scientific study is beginning to define the mechanisms 
that underlie neural and cortical recovery from stroke. (91) 
Post stroke therapeutic interventions should be appropriately timed and directed toward 
the specific neural substrate to maximize cortical reorganization. It is recognized that 
the earlier the implementation of therapy, the better functional outcome. (67) A 2005 
American Stroke Association endorsed Clinical Practice Guideline recommends that 
rehabilitation therapy starts as soon as possible. (19) 
There are four primary areas of focus for therapeutic rehabilitative intervention in stroke 
patients: mobility, self-care, language deficits and swallowing impairment. The 
rehabilitation physician also plays a role in detecting and treating spasticity and mood 
disorders following stroke. (91) 
The developing evidence- based methodologies that are becoming the foundation for 
stroke rehabilitation, will likely improve the efficacy and efficiency of rehabilitation 
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interventions. Through this process, stroke survivors will continue to experience better 
functional outcomes and ultimately, a better quality of life. (91) 
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3. AIMS AND HYPOTHESIS 
 
3.1 AIMS 
The aim of this study is to characterize the regional patterns of neural and axonal injury 
following Endothelin-1(ET-1) induced focal cerebral ischemia in immature rats. 
 
Description of the lesion:  
I. Assessment of gray matter damage and white matter damage (axons and 
oligodendrocytes) with use of conventional morphological techniques 
II. Assessment of the correspondence between white matter injury location and 
regional neurodegeneration. 
III. The injury will be assessed qualitatively.  
 
 
3.2 HYPOTHESIS: 
 
I. We hypothesized that damage to both, neuronal perikarya and axons; occur 
following ET-1 induced focal cerebral ischemia. 
II. We assume that the disappearance of stained myelinated fibers and the appearance 
of pathological myelin structures corresponds well to the degeneration of neurons 
taking place following ET-1 induced focal cerebral ischemia. 
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4. METHODS 
 
4.1 ANIMALS AND SURGERY 
 
4.1.1 CHARACTERIZATION OF THE GROUP OF ANIMALS 
Experiments were performed in Wistar albino rats on postnatal day 12 (P12; n= 9), or 
25 (P25; n= 10). The day of birth was defined as day 0. Rats were housed in a 
controlled environment (temperature 22 ± 1°C, humidity 50-60%, lights on 06:00-18:00 
h) with free access to food and water. Experiments were approved by the Animal Care 
and Use Committee of the Institute of Physiology of the Academy of Sciences of the 
Czech Republic. Animal care and experimental procedures were conducted in 
accordance with the guidelines of the European Community Council directives 
86/609/EEC. 
 
4.1.2 PRODUCTION OF FOCAL CEREBRAL ISCHEMIA 
Endothelin-1 is generally considered the most potent vasoconstrictor with a long/lasting 
action. Injection of ET-1 into the brain parenchyma has been found to induce substantial 
reduction of local blood flow followed by development of focal lesion. Recently focal 
injection of ET-1 was proposed as a highly reproducible model of human stroke. (92) 
The ET-1 model of focal cerebral ischemia incorporates reperfusion.  
Surgery was performed under halothane anesthesia. Anesthesia was induced in an 
inductory chamber and then the animals were placed into a stereotaxic apparatus with a 
breathing mask adapted for neonatal rats for continuous delivery of anesthesia. Rat pups 
were maintained at 0.8 - 1.5% halothane throughout the rest of procedure. Cannula for 
Endothelin-1 infusion (PlasticsOne, Bilaney – Germany; outer diameter 0.2mm) was 
inserted into left hemisphere at coordinates AP= 0; L= 2; V= 2 in P12 and AP= 0; L= 2; 
V= 2.5 relative to bregma in P25 animals.   
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Endothelin-1 (#E7764, Sigma, St Louis, MO, U.S.A.) was dissolved in 0, 01 M 
phosphate buffered saline (PBS, pH 7, 4) and infused using an infusion pump (KDS210, 
KD Scienrific, Holliston, MA, U.S.A.; 1µl/5min) to freely moving animals. Controls 
received 0, 01 M PBS in corresponding volume instead of ET-1 solution (P12 n=, 
P25n=). The dose of ET-1 used in both age groups was 40 pmol. After the injection, the 
cannula was kept in place for 5 minutes to prevent capillary rising to the cannula track.  
 
4.2. HISTOLOGY 
 
4.2.1 FIXATION 
All rats were deeply anesthetized with urethane (2.5 g/kg, i.p.) and transcardially 
perfused according to Timm-fixation protocol (one of the staining techniques that have 
been made on the slices) with 0.37% sulfide solution (1 ml/g) for 10 minutes followed 
by 4 % paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 (1 ml/ g), +40C, for 10 
minutes. The brains were removed from the skull and postfixed in buffered 4% 
paraformaldehyde for 3 hours and then cryoprotected in gradual sucrose (10, 20 and 
30%) at +40C. Then the brains were frozen in dry ice and stored at -700C. 
The brains were sectioned in the coronal plane (50 µm, 1-in-5 series) with Cryocut 
Leica 1600 and sections were stored in a cryoprotectant tissue-collecting solution (30% 
ethylene glycol, 25% glycerol in 0.05 M sodium phosphate buffer) at -200C until 
processed. Adjacent series of sections were used for Fluoro-Jade B and Black Gold 
staining. 
 
4.2.2 FLUORO-JADE B STAINING 
To detect and localize degenerating neurons, adjacent series of sections were processed 
for Fluoro-Jade B. This fluorescent marker of neuronal degeneration was obtained from 
Histo-chem (USA). 
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The sections were mounted on 2% gelatin coated slides and then air dried on a slide 
warmer at 50°C for at least half an hour. The slides were first immersed in a solution 
containing 1% sodium hydroxide in 80% alcohol (20 ml of 5% NaOH added to 80 ml 
absolute alcohol) for 5 min. This was followed by 2 min in 70% alcohol and 2 min in 
distilled water. The slides were then transferred to a solution of 0,006% potassium 
permanganate for 10 min, preferably on a shaker table to insure consistent background 
suppression between sections. The slides were then rinsed in distilled water for 2 min.  
The staining solution was prepared from a 0, 01% stock solution of Fluoro-Jade B that 
was made by adding 10 mg of the dye powder to 100 ml of distilled water. To make up 
100ml of staining solution, 4 ml of the stock solution was added to 96 ml of 0,1% acetic 
acid vehicle. This results in a final dye concentration of 0, 0004%. The stock solution, 
when stored in the refrigerator was stable for months, whereas the staining solution was 
prepared within 10 min of use and was not reused. After 20 min in the staining solution, 
the slides were rinsed for one min in each of three distilled water washes. Excess waster 
was removed by briefly draining the slides vertically on a paper towel. The slides were 
then placed on a slide warmer, set at approximately 50°C, until they were fully dry (e.g. 
5-10 min). The dry slides were cleared by immersion in xylen for at least a min before 
coverslipping with Canadian balsam, a non-aqueous, non-fluorescent plastic mounting 
media. 
 
4.2.3 BLACK-GOLD STAINING 
A novel haloaurophosphate complex called Black-Gold has been synthesized and 
applied to localize myelin within the central nervous system. The technique is tailored 
to studies using formalin fixed non-solvent processed tissue. The technique stains large 
myelinated tracts dark red-brown, while the individual myelinated axons appear black. 
Black-Gold is a sensitive method for detection of pathology in excitotoxin-induced 
myelin morphology. (82) 
This bright field myelin stain was obtained from Histo-chem (USA). Slide-mounted 
sections were rehydrated for 2 min in distilled water, and incubated for 15 min at 60°C 
in a solution of 0, 2% Black-Gold dissolved in 0, 9% saline. The sections were briefly 
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washed in distilled water and then intensified by incubation for 15 min at 60°C in 0,2% 
potassium tetrachloroaureate dissolved in 0,9% saline. Slides were rinsed in distilled 
water for 1 min, and then fixed in 2% sodium thiosulfate solution for 3 min. The slides 
were subsequently rinsed for 5 min in each of three changes of tap water. Sections were 
then dehydrated with gradated alcohol solutions and by air drying with a slide warmer. 
Dehydrated slides were then briefly cleared by immersion in xylene and coverslipped 
with Candian balsam. 
 
4.4 ANALYSIS  
In order to detect and localize degenerating neurons, each FJB-stained section through-
out the brain was analyzed. Damage extension was evaluated separately in individual 
areas of the brain (e.g. the hippocampus, the neocortex).  
To recognize the morphological features of the brain, each sample was compared to 
anatomical atlas of Paxinos and Watson. (70)  
The tissue was examined using an epifluorescent microscope Olympus AX70 with high 
sensitive cooled 3CCD digital camera Olympus DP70.  
Sections stained with Black-Gold were matched using anatomical landmarks (70) and 
inspected by light microscopy. As described before the technique stains large 
myelinated tracts dark red-brown, while the individual myelinated axons appear black. 
This novel tracer localizes both normal and pathological myelin.  
Damaged areas were mapped onto coronal sections in the atlas of Paxinos and Watson. 
(70) For the microscopy, lenses with 2x, 10x, and 20x magnification were utilized. 
The investigator who evaluated the extent of damage was blind to the status of the 
animals. 
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5. RESULTS 
 
5.1 GENERAL OBSERVATIONS 
Ischemic damage to neuronal cells and to myelin was observed in all animals with 40 
pmol of ET-1. In contrast, the sections from vehicle treated animals revealed minimal 
neuronal cell body damage, limited to a small area at the injection site. ET-1 caused 
neuronal degeneration in a bigger area surrounding the injection site, indicated by the 
presence of FJB-positive cells. Image analyses performed on stained brain sections after 
ET-1 administration, revealed damage that encompassed cortical, alveolar, callosal and 
in some animals even hippocampal regions ipsilateral to the ET-1 injection. 
Contralateral hemispheres revealed the typical normal pattern of labeling for each 
respective marker in both age groups of animals. Specifically, the FJB staining resulted 
in virtually no label within the brain itself. Occasionally a relatively small number of 
FJB-positive neurons were found in the contralateral hemisphere of both animal groups. 
This slight apparent damage varied from animal to animal and varied somewhat across 
medial to lateral extent of the brain and was possibly associated with mechanical effects 
of the injection, of craniotomy, or its impact on the brain removal process. 
Black-Gold staining resulted in the conspicuous labeling of all myelinated fibers within 
all brain regions examined.  
A constant feature in all animals was that the extent of the lesion seemed bigger in more 
coronal planes located more caudally from the injection site than rostrally from the 
injection site. 
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5.2 PATHOLOGICAL FEATURES OF AXONS, 
OLIGODENDROCYTES AND DAMAGED NEURONAL 
PERIKARYA IN THE CEREBRAL CORTEX 
Neuronal damage was found in the cortex surrounding the injection site in both animal 
groups. The wide-spread of the area, where degenerating neurons were observed in the 
ET-1 treated animals was bigger than the area, where this type of damage was found in 
sham operated animals. Only sparse FJB-positive neurons were detected in the close 
vicinity of the cannula track and in the injection site in vehicle treated animals.  
 
A  B  
 
Figure 3. Intensely Fluoro-Jade B labeled cells (indicated with arrows) are observed in 
the penumbra immediately adjacent to the injection site in the ipsilateral cortex of the 
ET-1 treated animals (A) and in the animals from the control group (B). The wide-
spread of Fluoro-Jade positive cells is larger in ET-1 treated animals (A) as compared to 
animals from the control group (B). Scale bar= 500 µm. 
 
Pathologic features of myelin and myelin loss was observed in the cortical region 
adjacent to the injection site in both, ET-1 and sham group. The wide-spread of damage 
to myelin seems bigger in the ET-1 group as compared to the control group. An overt 
loss of myelinated fibers was observed in the ipsilateral cortex as compared to the 
contralateral cortex in both groups. Myelinated fibers in the cortex immediately 
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adjacent to the cannula track and the injection site were not apparent, but with growing 
distance from the cannula track and injection site, myelin fibers gradually appeared. A 
very moderate level of myelin damage was apparent in sham stroke control animals 
within a similar region to animals, which underwent the application of the ET-1 
injection. (See att. 2-3) 
In the lower layers of the cortex of the ET-1 treated animals a typical pattern of injury to 
myelin was observed in the coronal sections located caudally from the coronal section, 
where the injection site is detected. 
In the cortical layer VI: 
• Myelinated fibers appeared shorter, more divergent and their density decreased 
relative to sham and to the contralateral hemisphere of the same animal. 
• The density of myelinated fibers of the cell layer VIa), where more vertically 
oriented pyramidal cells are located, decreased more than in the VIb) layer, 
where cells are oriented more horizontally. 
• Observation of the myelin in layer VI  within the ipsilateral cortex to the ET-1 
injection revealed bead-like myelin structures. They were located well beyond 
the surface, where FJB-positive cells were found. (see att. 4) 
In cortical layer V: 
• The extent of ischemic damage was also of interest in this layer as cortical 
neurons in this layer are the major output neurons of the cortex that synapses 
with the midbrain, hindbrain and spinal cord, ultimately affecting motor 
function. 
• In the sections immediately following the injection site, the disappearance of 
myelinated fibers in this layer was observed, suggesting that there are no fibers 
leaving, coming to or passing through this layer. (see att. 5) 
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Our observations of the layers V and VI revealed that the spatial spread of the ischemic 
damage to the white matter extended further laterally than the spread of FJB-positive 
cells. 
Although the size of the ischemic lesion decreased the further the section was located 
from the injection site, the lateral spread of damage to neuron cells remained relatively 
confined to the localization of the injection site in all animals. However, the damage to 
myelin seems to spread more septally in more caudal coronal planes following after the 
section, in which the injection site is detected.  
A  B  
C  
Figure 5. Fluoro-Jade B staining and Black-Gold staining of an ET-1 treated animal 
coronal section located further caudally from the injection site (A-C). Fluoro-Jade 
staining reveals the presence of degenerating neurons in the ipsilateral cortex (white 
arrows indicate the wide-spread of degenerating neurons) (A).An adjacent Black-Gold 
labeled section demonstrates, that the localization of damage to myelin (black arrow) in 
the ipsilateral cortex is located more septally (B, C) in comparison to the localization of 
the degenerating neurons. Scale bar (A, B) = 500 µm, scale bar (C) = 100 µm. 
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5.3 PATHOLOGICAL FEATURES OF AXONS, 
OLIGODENDROCYTES AND DAMAGED NEURONAL 
PERIKARYA IN THE HIPPOCAMPUS 
Hippocampal injury was evident in 5 (P12=2, P25=3) animals from the ET-1 group in 
both Black-Gold and FJB staining. Damage was located in the dorsal part of the 
ipsilateral hippocampus. In controls, no FJB-positive neurons and no myelin pathology 
was detected neither in the ipsilateral nor in the contralateral HC. 
A  B  
C  D  
Figure 6. Distribution of FJB– positive cells in the ipsilateral hippocampus of an ET-1 
treated animal (A). The ipsilateral hippocampus of a control animal is free of FJB– 
positive cells (B). Black-Gold staining reveals damage to myelin in the ipsilateral 
hippocampus of an ET-1 treated animal (C). In the ipsilateral hippocampus no myelin 
pathology is observed (D). Scale bar (A, C) = 100 µm, scale bar (B, D) = 500 µm. 
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FJB labeled cells were most consistently noted in the ipsilateral stratum pyramidale and 
stratum radiatum of the CA1/2 border and CA1 area of the HC, whereas the 
contralateral HC is unlabeled. The CA3 area of the HC in both age groups was free of 
FJB-positive cells. 
A  B  
C  D  
E  F  
Figure 7. Fluoro-Jade B labeling in the ipsilateral (A, C, E) versus the contralateral (B, 
D, F) cortex in both, in a P12 ET-1 treated animal (A, B) and in a P25 treated animal (C, 
D), and in an animal from the contol group (E, F). Fluoro-Jade B positive cells are 
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observed throughout the ipsilateral hippocampus including the cells in stratum 
pyramidale, stratum radiatum and stratum oriens of the border of the CA1 and CA2 area 
of the hippocampus and in the CA1 area of the hippocampus (white arrows), whereas 
the contralateral hippocampus is unlabeled (B, D, F). The CA3 area of the hippocampus 
is free of Fluoro-Jade B positive cells (red arrows) in the ipsilateral and contalateral 
hippocampus (A-F). Scale bar= 500 µm. 
 
The distribution of FJB-positive cells in the CA1 area of the HC of the ET-1 treated 
animals exhibited a specific „patchy pattern“, described by G. Tsenov et al. (se att.6) 
The investigation of the presence of myelinated fibbers in the HC subregions in the 
control groups revealed that most of the CA3 projections projected septally. In contrast, 
in the CA1 region, the overwhelming majority of myelinated fibers projecting from this 
hippocampal subfield were found in the stratum radiatum. Most myelinated fibers in the 
CA1 region were emitted caudally. (See att. 7) 
Differences between the sham and the ET-1 group were detected in the intensity of 
Black-Gold staining in the inspected subregion of the HC. In the control group, there 
was no evidence of myelin loss. 
Myelin loss was observed in the ipsilateral stratum oriens et radiatum of the 
hippocampal CA1/2 border and CA1 in all the 5 mentioned animals from the ET-1 
group, as compared to the contralateral hemisphere of these animals.  This myelin loss 
was located within a similar region in which FJB-positive cells were detected in these 
animals. (See att. 8) 
Despite the fact that myelinated fibers disappeared in the CA1 area of the hippocampus 
in all the 5 mentioned ET-1 treated animals, pathological myelin structures were 
apparent in the CA3 hippocampal subregion of the two P12.  
Black-Gold staining revealed lesion-induced myelin pathologies in this region. Labeling 
of this region is more subtle in comparison to the contralateral hippocampus. 
Varicosities, tumescences and bead-like myelin structures are present in the affected 
zone. The myelinated fibers seem to be shorter, more divergent and show more complex 
branching patterns.  
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A   B   
C   D   
E   F  
Figure 8. Lesion-induced myelin pathologies in the ipsilateral CA3 hippocampal area 
of a P12 ET-1 treated animal (A, C, E) versus the contralateral CA3 hippocampal area 
(B, D, F). Black-Gold labeling is more subtle in the stratum radiatum of the CA3 
hippocampal area and the Black-Gold positive fibers seem to be shorter and more 
divergent (C) in comparison to the contralateral CA 3 region (D). The arrows indicate 
bead-like structures of pathological myelin in the fimbria of the fornix and in the 
stratum radiatum of the CA3 area of the ipsilateral hippocampus (E) as compared to the 
contralateral hippocampus (F). Scale bar (A, B) = 500 µm, scale bar (C-F) = 100 µm. 
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Labeling of the hilus is more subtle in the ipsilateral hemisphere of the ET-1 treated 
animals in comparison to the contralateral hemisphere of the same animals. (See att. 9) 
With the caudal extent of the lesion from the injection site, we can observe that the 
ischemic damage in the CA1 hippocampal area spreads septally. In the coronal section 
immediately following the injection site in the caudal direction, the ischemic damage is 
located at the CA1/2 border. However, in more caudal coronal planes,  following the 
mentioned section where the injection site is detected,  the ischemic damage is located 
only in CA1 and tends to spread more septally the bigger the distance (in the caudal 
direction) from the injection site is. 
         
 
 
 
Figure 9. The schematic drawing illustrates the extension of hippocampal damage in a 
P12 ET-1 treated animal. Grey areas symbolize the segments with Fluoro Jade B-
positive cell bodies. The schematic drawing modified from Paxinos and Watson, 1998. 
(71) 
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The hippocampus appeared to be more extensively injured in P12 than in P25 ET- 1 
treated animals as demonstrated by a bigger wide-spread of FJB labeled structures and 
by the disappearance of myelin and/or the presence of pathological myelin structures in 
the cornu ammonis and hilar region. 
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6. DISCUSSION 
 
6.1. DISCUSSION- THE RESULTS  
There is a substantial need to understand the vulnerability of the developing brain to 
focal cerebral ischemia. In this study we describe and characterize the regional patterns 
of neuronal injury and axonal degeneration after ET-1 induced focal cerebral ischemia 
in immature rats at postnatal day 12 and 25. 
 
6.1.1 DAMAGE TO WHITE AND GRAY MATTER IN THE 
IPSILATERAL CEREBRAL CORTEX 
Our findings demonstrate that ET-1 induced focal cerebral ischemia in the developing 
brain generates neuronal and myelin loss in the ipsilateral cerebral cortex of both age 
groups of immature rats. It also causes a distinct pattern of subcortical neuronal injury 
and the wide-spread of white matter damage.  
The results suggest that the cerebral white matter is highly vulnerable to the effects of 
focal cerebral ischemia. Pathological structures of myelin and the loss of myelinated 
fibers in the cerebral cortex seem to be concomitant with the presence of degenerating 
neurons. However, it seems that the spatial spread of damage to myelin extends further 
laterally throughout the cortex than does damage to neuronal cells.  
Analyses of areas of pathology in the cerebral cortex in coronal sections revealed that at 
more caudal coronal planes the location of damage to myelin appears more septally than 
in more rostral coronal planes. This observation contrasted strikingly with the finding in 
control animals where damage to white matter remained confined to the location of gray 
matter damage. This septall spread of damage to myelin observed on caudal coronal 
planes could be due to the course and ramification of the vasoconstricted vessel. 
The pathogenesis of demyelination after ischemia may be due to loss of mature 
oligodendrocytes or may be secondary to other processes such as microglial activation 
or loss of trofic support after axonal degeneration (32).  
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Many studies show that oligodendrocytes are vulnerable to a variety of hypoxic insults. 
Cerebral ischemia is known to cause a variety of changes as energy failure owing to the 
lack of oxygen and glucose, excitotoxity and free radical formation that include nitric 
oxid and TNF-α production, all of which are toxic to oligodendrocytes. (83) 
Our data suggest that the white and gray matter damage is not the same in different 
cortical layers. Layer VI and especially layer V seems to be more vulnerable to 
ischemia than the other cortical layers.  
It has previously been established that certain subsets of neurons, including layer 
V neurons, are particularly vulnerable to ischemic damage. (21) 
Layer V contains large, burst-firing pyramidal cells with long apical dendrites. These 
large cells project, depending on cortical area, to subcortical regions such as the 
superior colliculus and the pons. (89) 
An explanation for the vulnerability of the cells in the cortical layer V is that the higher 
surface area to volume ratio of axonal processes makes them not able to buffer aberrant 
ion influxes as efficiently as other neuronal cell populations, thus making them more 
susceptible to ischemia/excitotoxicity. (21) 
Furthermore the damage to gray and white matter in this layer could be associated with 
the degenerating cells in the VI layer. Local axon collaterals of these cells arborize 
primarily in layer V and VI in S1 and the callosum. (89) 
It is also possible that processes in deeper cortical regions than layer V are less ischemic 
because of redundant horizontally oriented blood flow derived from adjacent territories 
that are less ischemic. (21) 
 
6.1.1 DAMAGE TO WHITE AND GRAY MATTER IN THE 
IPSILATERAL HIPPOCAMPUS 
White and gray matter damage in 5 ET-1 treated animals was detected in the ipsilateral 
subcortical white matter with the involvement of the alveus, corpus callosum and the 
hippocampus. Degeneration of the subcortical white matter could be due to the loss of 
cortico-cortical innervations following loss of neurons in the ipsilateral cortex. (90) 
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This degeneration could also be the result of the contusive effect of the craniotomy or of 
the mechanical effects of the injection or of the brain removal process. The diffusion of 
released cytotoxic factors such as glutamate, nitric oxide, or other factors from the 
dying core could lead to the mentioned degeneration. (98) 
To detect degenerating neuronal cells we used Fluoro Jade B (81), which is capable to 
label dying neurons in a wide variety of contexts, regardless of the mechanism of cell 
death. Fluoro Jade B-positive cells were observed only in the CA1 area of the ipsilateral 
hippocampus and are located "under" the ischemic core in the cortex.  
Following ET-1 induced focal cerebral ischemia, a specific degeneration takes place in 
the hippocampus, accompanied by the loss of myelinated fibers and the appearance of 
pathological myelin structures. In the CA1 hippocampal area the loss of myelin was 
visible in the adjacent coronal sections to those, in which degenerating neurons were 
observed.  
Pathological features of myelin and the loss of myelinated fibers was observed in the 
CA3 hippocampal area of all the P12 ET-1 treated animals, which exhibited white 
matter damage in subcortical regions. No Fluoro Jade B-positive cells were found in 
this hippocampal region in the same animals. The absence of Fluro Jade B-positive cells 
in the CA3 hippocampal region of these animals could be due to their distance from the 
injection site that is too big for the diffusion of cytotoxic factors to lead to degeneration 
of cells in this hippocampal region. Subtle Black-Gold labeling was observed in the 
ipsilateral hilus in all ET-1 treated animals, which exhibited white matter damage in 
subcortical regions. No Fluoro Jade B-positive cells were found in this hippocampal 
region in the same animals. The absence of Fluro Jade B-positive cells in this region of 
these animals could also be due to their big distance from the injection site. 
The presence of myelin pathological structures and the loss of myelinated fibers in the 
hilus, CA1 and CA3 area of the ipsilateral hippocampus could be linked. Adult CA 
pyramidal cells have been shown to project not only to CA 1 area in the Schaffer 
collateral pathway, but also toward the hilus of the dentate gyrus. 
 The damage in the CA1 hippocampal area to gray and white matter was observed in the 
coronal section, which showed the injection site, at the CA1/CA2 boarder of these 
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hippocampal areas. However, in more caudal coronal planes, the damage to white 
matter was confined only to the CA1 area of the hippocampus. We could speculate, that 
the mentioned observed spatial pattern of ischemic damage in the CA1 hippocampal 
area is related with the damage to the white matter of the CA3 hippocampal area. 
As mentioned, all portions of CA3 and CA 2 project to CA1 but the distribution of 
terminations in CA1 depends on the transverse location of the CA3/CA2 cells of origin. 
CA3 cells located close to the dentate gyrus (proximal CA3), while projecting both 
septally and temporally for substantial distances, tend to project to levels of CA1 
located septal to their location. CA3 cells located closer to CA1, in contrast, project 
more heavily to levels of CA1 located temporally. At, or close to, the septotemporal 
level of the cells origin, those cells located proximally in CA3 give rise to collaterals 
that tend to terminate superficially in the stratum radiatum with a clear preference for 
the more distal portions of CA1 (near the subicular boarder). Conversely, cells of origin 
located more distally in CA3 give rise to projection that terminate deeper in the stratum 
radiatum and the stratum oriens, with a preference for portions of CA1 located closer to 
the CA2 boarder.(1)  
A key question is whether the developing brain exhibits a degree of vulnerability 
different from that of the adult brain after focal cerebral ischemia. There is evidence for 
age-related differences in the presence of myelinated fibers in the developing 
hippocampus. (54, 29, 98) These differences may influence the extent of damage to 
white matter in animals of different ages.  
Although entorhinal fibers first reach the dentate gyrus at embryonic day 19, the 
perforant path is almost formed at postnatal day 5. Light and ultrastructural analyses 
revealed that mature fibers in the hippocampus occur in the second postnatal week. 
During postnatal development, increasing numbers of myelinated fibers appear and the 
distribution of myelinated fibers at postnatal day 25 is similar to that found in the adult. 
(54) 
During early postnatal life, there is an exuberant outgrowth of local CA3 recurrent 
axons, and with maturation these recurrent collaterals are remodeled. The number of 
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axon branches decreases by 50% in adulthood in comparison with the second postnatal 
week. (29) 
The extension of the damage in the ipsilateral hippocampus of P12 ET-1 treated animals 
is higher than in P25 treated animals. This observation could be the consequence of the 
mentioned alterations of the degree of myelination in animals of different ages. Studies 
demonstrated that ET receptors are over expressed during early postnatal development; 
therefore ET-1 might be more effective in P12 than in P25 rats. (92) 
 
6.2. DISCUSSION- THE METHODOLOGY 
Some errors might appear in our conclusions. The protocol of the surgical procedure is 
relatively free from major problems. Care must be taken, when implanting the cannula 
for ET- 1 infusion at the right coordinates. Since the animals are very young, 
manipulation with their body must done with big care in order to prevent mechanical 
insults to the brain tissue.  The errors in conclusions arise mostly from the histological 
procedure. During fixation, cryoprotection and freezing brain tissue shrinks and thus 
influences the observations. This could be neglected in the case that the tissue from the 
control and experimental groups shrink similarly. (40) 
We assessed neuronal and axonal injury by means of qualitative morphologic methods. 
In this study we used the myelin-specific marker Black-Gold to localize normal and 
pathological myelin (82) and Fluoro Jade B, an anionic fluorescein derivate, to stain 
neurons undergoing degeneratinion (81). 
Studies of myelin in the CNS based on histochemical techniques have to be interpreted 
with some caution, as results may be influenced by the following factors: signal-to–
noise ratio, considerable variability in staining, staining of unknown molecules and 
complex multi-step prestainig procedures. (54) 
Based on the fact, that Black-Gold is a gold chloride dye, one may speculate on the 
possibility that Black-Gold binds to other for the present unknown molecules. This 
could lead to falsely negative findings. And thus the brain sections of all animals were 
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Black-Gold stained in two Black-Gold 0,2% staining solutions in order to prevent 
variability in staining due to the exhaustment of the staining solutions.  
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7. CONCLUSIONS 
Collectively, our observations support the hypothesis that damage to neuronal cells and 
myelinated axons occurs in the rat brain following Endothelin-1 induced focal cerebral 
ischemia. Our data emphasize the profound effect that focal cerebral ischemia has on 
both gray and white matter in the immature rat brain. 
Our results strongly suggest that pathological changes in myelinated fibers appear to be 
concomitant with neuronal injury. However, the spatial spread of the damage to 
myelinated fibers seems to be bigger than is the extent of the area, where degenerating 
neurons were detected. 
What triggers the damage to myelinated fibers in our model of focal cerebral ischemia 
remains to be elucidated. Our findings did not establish a cause-and-effect relationship 
between the white matter damage and gray matter damage. To investigate such 
functional outcome, further experiments would be of interest. 
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8. ABBREVIATIONS 
AMPA - α-amino-3-hydroxy-5- methylisoxazole-4-propionic acid  
ATP - Adenosine triphosphate 
CA1-4 - Region 1-4 of the Cornu Amonnis 
CBF - Cerebral Blood Flow 
CNS - Central Nervous System 
CNTF - Ciliary neurotrophic factor 
DNA - Deoxyribonucleic acid 
DG - Dentate Gyrus 
EC - Entorhinal Cortex 
EEG - Electroencephalography 
ET-1- Endothelin-1 
FJB - Fluoro Jade B 
IGF-1- Insulin-like Growth Factor 1 
FCI - Focal Cerebral Ischemia 
FGF-2 - Fibroblast Growth Factor 2 
HC - Hippocampus 
HDL- High Density Lipoprotein 
MAG - Myelin-Associated Glycoprotein 
MBP - Myelin Basic Protein 
NMDA - N-methyl-D-aspartate 
NT-3 - Neutrophin 3 
OCs - Oligodendrocytes 
OMgp - Oligodendrocyte-Myelin Glycoprotein 
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OPCs - Oligodendrocyte Precursor Cells 
PDGF-A - Platelet Derived Growth Factor 
PLP- Proteolipid Proteins 
PNS - Peripheral Nervous System 
TIA - Transient Ischemic Attack 
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10. ATTACHMENTS 
Attachment No. 1 
 
 
 
 
 
 
Diagram of the rat hippocampus. Drawings of the rat brain showing the three-
dimensional organization of the hippocampus and related structures. Three coronal 
sections through the left hippocampus are shown at the bottom right of the figure, with 
their approximate anteroposterior coordinate relative to bregma. CA1, CA2, CA3: cornu 
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ammonis fields 1–3; DG: dentate gyrus; EC: entorhinal cortex; f: fornix; s: septal pole 
of the hippocampus; S: subiculum; t: temporal pole of the hippocampus. (14) 
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Attachment No. 2 
A   B   
C   D  
 
Fluoro-Jade B labeling (A, C) versus Black-Gold labeling (B, D) in the ipsilateral cortex 
in an animal from the control group. Fluoro-Jade positive neural profiles and the 
disappearance of myelin are observed in the close vicinity of the cannula track and in 
the close vicinity of the injection site. Scale bar (A, B) = 500 µm, scale bar (C, D) = 100 
µm. 
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Attachment No. 3 
A   B  
C   D  
E   F  
 
Prominent Fluoro-Jade B labeling is apparent in the ipsilateral cortex surrounding the 
cannula track and the injection site. (A, C, E) in the cortex of an ET-1 treated animal. 
Adjacent Black-Gold sections reveal white matter degeneration in similar regions (B, D, 
and F) in the same animal. Scale bar= 100 µm. 
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Attachment No. 4 
A   B  
C   D  
E   F  
 
Black-Gold staining reveals changes in the presence of myelin in the VI layer of the 
cortex in coronal sections of ET-1 treated animals (A- E). Black-Gold positive fibers in 
the ipsilateral cortex surrounding the injection site appeared shorter, more divergent and 
their density decreased (A) relative to the contralateral hemisphere (B). In the ipsilateral 
 82 
cortex mildly labeled fibers are visualized in the white matter of the VI a) cell layer and 
somewhat weaker staining is detected in the VI b) Layer (C), whereas Black-Gold 
positive fibers are present in both subunits of the VI cortical layer in the matching 
region of the contra lateral cortex (D). Bead-like myelin structures are present in the VI 
layer of the ipsilateral cortex surrounding the injection site (E). The contralateral cortex 
is devoid of bead-like myelin structures (F). Scale bar (A-D) = 100 µm, Scale bar (E, F) 
= 100 µm. 
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Attachment No. 5 
 
A  
B   C  
D   E  
 
Black-Gold staining of an ET-1 treated P25 rat (A-C) and of an ET-1 treated P12 rat. 
The V. layer of the ipsilateral cortex of ET-1 treated animals (A, B, C), adjacent to the 
injection site, appears devoid of Black-Gold stained fibers relative to the contralateral 
cortex (A, C, E). Scale bar (A) = 500 µm, scale bar (B-E) = 100 µm. 
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Attachment No. 6 
 
 
The distribution of Fluoro Jade B-positive cells in a P12 animal after infusion of ET-1. 
Fluoro Jade B-positive neurons (indicated by arrows) in the pyramidal cell layer of 
CA1. Scale bar= 500 µm. 
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Attachment No. 7 
 
 
Black-Gold stained hippocampal coronal sections from a control animal. Most of the 
CA3 hippocampal area projections are present septally (white arrows) projections from 
the CA1 hippocampal area are emitted ventrally (black arrows). Scale bar= 500 µm. 
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Attachment No. 8 
 
A  B  
 
Black-Gold staining of the hippocampus of an ET-1 treated animal. There is an overt 
loss of black-Gold stained fibers in the stratum oriens and radiatum (arrows) of the CA1 
hippocampal area (A), as compared to the contralateral hemisphere (B). Scale bar= 500 
µm. 
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Attachment No. 9 
 
A   B  
C   D  
 
Regional characterization of damage to the white matter in the hilus, as seen with 
Black–Gold labeling in the hippocampus of a P12 ET-1 treated animal (A, B) and a P25 
ET-1 treated animal (C, D). There is a pronounced loss of myelinated fibers in the hilus 
of the ipsilateral hippocampus (A, C) as compared to the contralateral hilus (B, D). 
Scale bar= 100 µm. 
 
 
 
 
 
